Compared with the standard of care (SoC) and investigational agents, M4205 has superior potency against a range of KIT mutations and a best-in-class kinase selectivity profile translating into clinically meaningful antitumor activity in a broad panel of GIST xenograft models. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.